Mark Rothera

Mark Rothera is a declared insider at 2 companies; the most frequent names are PTC Therapeutics, Inc. and Viracta Therapeutics, Inc. The record holds 48 filings, for trades running from 25 June 2013 to 1 December 2023.

In open-market terms, that means 4 purchases worth €343k on one side and 21 sales worth €4.4M on the other. Sales outweigh purchases by €4.1M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant and 22 option exercises. So far in 2023, the count stands at 2 purchases and no sales.

In size, the median ticket on the buying side is €23k. No cluster: in 3 purchases, no other insider of the company bought within 30 days.

Most recently, on 4 December 2023, the filings show an open-market purchase worth €22k in Viracta Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.